HAQDIHealth Assessment Questionnaire Disability Index
References in periodicals archive ?
In the third study, also conducted in Europe, the HAQDI improved in both the leflunomide and methotrexate groups.
Abramson, chairman of rheumatology and medicine at the Hospital for Joint Diseases, New York, said he accepted that leflunomide had an effect on the HAQDI on earlier time points, but was not so sure about the 2-year end point.
These improvements were sustained until week 12, by which time significant improvement from baseline was observed for all doses of tofacitinib as compared to the placebo in these categories as well as in HAQDI score, patient and physician global assessment, swollen joint counts, and pain.